Skip to content
Screener

Indivior Pharmaceuticals, Inc. INDV Price / earnings

Price / earnings at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
24.5×-2.2×
Alkermes logo
AlkermesALKS
132.1×+118×
Emergent Biosolutions logo
Emergent BiosolutionsEBS
6.2×—

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.57B+66.3%
Enterprise value$4.9B+88.3%
P/S3.5×+1.2×

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%—

Returns & leverage

See full
Return on equity-117%—
Debt / equity-3.5×—
Current ratio0.9×0.0×

Where this comes from

Calculated from Indivior Pharmaceuticals, Inc.’s reported figures.

market cap/net income=14.8×

Based on the most recent quarter.

The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026. Open the filing →

Filed
Apr 30, 2026, 4:02 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028850

FAQ

What is Indivior Pharmaceuticals, Inc.'s price / earnings?
Indivior Pharmaceuticals, Inc. (INDV) reported price / earnings of 14.8× in Q1 2026.
What does price / earnings mean?
Market capitalization at the quarter end divided by trailing-twelve-month net income. The price the market pays for each dollar of trailing earnings.

Ask your AI about Indivior Pharmaceuticals, Inc.'s price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude